5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions

5.1 Stimulant Use Disorder: Neurotoxicity, Medical Emergencies & Evidence-Based Interventions

Quick Answer: Stimulant use disorders involve profound central and peripheral monoaminergic stimulation. Cocaine competitively inhibits presynaptic reuptake via DAT, NET, and SERT, while exerting class I local anesthetic sodium channel blockade that widens the QRS complex and predisposes to malignant ventricular arrhythmias. Methamphetamine acts as a transporter substrate that inhibits vesicular monoamine transporter-2 (VMAT-2) and triggers reverse-transport monoamine dumping, causing long-term terminal dopaminergic axonal pruning. Acute cardiovascular crises (coronary vasospasm, acute myocardial infarction, hypertensive emergency) must be treated with intravenous benzodiazepines, nitroglycerin, or phentolamine; pure beta-blockers are strictly contraindicated due to the risk of unopposed alpha-1 adrenergic vasoconstriction. Although no FDA-approved pharmacotherapies exist, the landmark ADAPT-2 trial demonstrated that combination extended-release bupropion (450 mg/day) plus injectable extended-release naltrexone (380 mg q3w) significantly improves methamphetamine abstinence. Across all modalities, Contingency Management (CM) maintains the highest effect size and strongest evidence base for stimulant abstinence.

---

1. Pharmacology & Neurobiology: Cocaine vs. Methamphetamine

Psychostimulants represent a chemically and pharmacologically diverse class of compounds that profoundly enhance monoaminergic neurotransmission—principally dopamine (DA), norepinephrine (NE), and serotonin (5-HT)—within the central and peripheral nervous systems. Understanding the precise molecular distinctions between cocaine and amphetamine derivatives is critical for advanced practice clinical management.

Presynaptic Monoamine Transporter Dynamics

Under baseline physiological conditions, the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) terminate monoaminergic signaling by clearing neurotransmitters from the synaptic cleft back into the presynaptic terminal. Once internalized, cytosolic monoamines are sequestered into synaptic storage vesicles by vesicular monoamine transporter-2 (VMAT-2), maintaining low free cytosolic concentrations and protecting monoamines from metabolic degradation by monoamine oxidase (MAO).

PHYSIOLOGICAL MONOAMINE CYCLE:  
[Presynaptic Terminal] ──DAT/NET/SERT Internalization──> [Cytosol] ──VMAT-2 Sequestration──> [Synaptic Vesicles]

COCAINE MECHANISM:  
[Synaptic Cleft] <── DAT/NET/SERT Blockade (Reuptake Inhibited) ── [Extracellular Monoamine Accumulation]

METHAMPHETAMINE MECHANISM:  
[Meth Enters via DAT] ── VMAT-2 Inhibition + pH Disruption ──> [Cytosolic Dumping] ── Transporter Reversal ──> [Massive Synaptic Flooding]

Cocaine: Competitive Reuptake Blockade & Sodium Channel Inhibition

Cocaine is a naturally occurring alkaloid extracted from the leaves of Erythroxylum coca. Its primary pharmacodynamic actions include:

• Competitive Reuptake Blockade: Cocaine binds directly to the external substrate-binding pocket of DAT, NET, and SERT without being transported into the neuron. By physically obstructing monoamine reuptake, cocaine causes immediate accumulation of dopamine, norepinephrine, and serotonin within the synaptic cleft, driving intense stimulation of post-synaptic receptors.
• Local Anesthetic & Membrane-Stabilizing Cardiotoxicity: Distinct from amphetamines, cocaine binds to and blocks voltage-gated sodium channels ($I_{\text{Na}}$) in myocardial tissue and peripheral nerves. This class IC antiarrhythmic-like membrane-stabilizing action slows Phase 0 cardiac depolarization, widens the QRS complex, prolongs the QTc interval, and significantly elevates the risk of re-entrant ventricular arrhythmias, torsades de pointes, and fatal ventricular fibrillation.
• Pharmacokinetics: Cocaine possesses a rapid elimination half-life of 0.5 to 1.5 hours. It is rapidly metabolized by hepatic and serum cholinesterases into benzoylecgonine (detection window in urine: 2 to 4 days; up to 1 to 2 weeks in chronic, high-dose users) and ecgonine methyl ester. When co-ingested with ethanol, hepatic transesterification synthesizes cocaethylene, a metabolite with a prolonged elimination half-life (2 to 2.5 hours), potent DAT binding, and exaggerated arrhythmogenic cardiotoxicity.

Methamphetamine: VMAT-2 Inhibition & Transporter Reversal

Methamphetamine is a synthetic, highly lipid-soluble methylated amphetamine with profound central nervous system penetrance and a markedly prolonged elimination half-life (10 to 12 hours):

• Substrate Uptake & Vesicular Depletion: Methamphetamine is structurally homologous to dopamine and acts as a competitive substrate for DAT, NET, and SERT. Once transported into the presynaptic terminal (and diffusing directly across the plasma membrane due to high lipophilicity), methamphetamine targets VMAT-2. It collapses the vesicular proton electrochemical gradient necessary for monoamine retention and competitively inhibits VMAT-2 function.
• Reverse Transport Dumping: Displacement of monoamines from storage vesicles causes an enormous accumulation of free cytosolic dopamine, norepinephrine, and serotonin within the nerve terminal. Methamphetamine subsequently activates protein kinase C (PKC) and CaMKII, prompting reverse transport (efflux) via DAT, NET, and SERT. The transporters reverse directionality, pumping massive surges of cytosolic monoamines into the synaptic cleft independent of neuronal action potentials.
• MAO Inhibition: Concurrently, methamphetamine acts as a competitive inhibitor of monoamine oxidase, preventing the intracellular breakdown of accumulated monoamines.

Terminal Axonal Pruning & Striatal Neurotoxicity

Unlike cocaine, which is primarily toxic via acute vascular and cardiac mechanisms, chronic methamphetamine exposure inflicts profound, long-lasting structural damage on central dopaminergic and serotonergic architecture:

1. Oxidative and Nitrosative Stress: The enormous accumulation of free cytosolic dopamine facilitates non-enzymatic auto-oxidation, generating neurotoxic dopamine quinones, hydrogen peroxide ($H_2O_2$), hydroxyl radicals ($,^\bullet\text{OH}$), and peroxynitrite ($\text{ONOO}^-$).
2. Axonal Pruning & Terminal Loss: Reactive oxygen and nitrogen species trigger mitochondrial permeability transition, deplete ATP, activate calpains/caspases, and induce direct damage to structural tubulin and actin microfilaments. This results in axonal pruning—the selective structural degeneration of presynaptic axon terminals in the striatum, caudate, and putamen, while sparing cell bodies in the substantia nigra and ventral tegmental area.
3. Long-Term Neurochemical Deficits: Positron emission tomography (PET) imaging in patients with chronic methamphetamine use disorder demonstrates profound reductions in striatal DAT density (up to 20–40% loss) and $D_2/D_3$ receptor availability that persist for 12 to 24 months of verified abstinence. Clinically, this manifesting as profound executive dysfunction, severe protracted anhedonia, apathy, psychomotor slowing, and treatment-resistant depressive states.

Comparative Overview: Cocaine vs. Methamphetamine

---

2. Acute Medical Emergencies & Crisis Management

Stimulant toxicity precipitates life-threatening medical crises spanning the cardiovascular, central nervous, and renal systems. The APRN in emergency, inpatient, or outpatient triage must rapidly recognize toxidromes and execute evidence-based medical resuscitation.

Cardiovascular Emergencies & The Unopposed Alpha-Stimulation Phenomenon

Acute stimulant intoxication triggers a triad of cardiovascular pathophysiology:

1. Severe Coronary Vasospasm: Mediated by intense post-synaptic vascular alpha-1 adrenergic receptor stimulation in epicardial coronary arteries.
2. Myocardial Oxygen Supply-Demand Mismatch: Concurrently, marked beta-1 adrenergic stimulation drives profound sinus tachycardia, increased inotropic contractility, elevated systemic vascular resistance, and severe systolic hypertension, drastically elevating myocardial work and oxygen consumption.
3. Platelet Aggregation & In Situ Thrombosis: Cocaine directly enhances platelet alpha-granule release, increases thromboxane $A_2$ production, elevates tissue factor and plasminogen activator inhibitor-1 (PAI-1), and damages vascular endothelium, promoting acute intracoronary thrombus formation even in angiographically normal vessels.

[!CAUTION] The Unopposed Alpha-Adrenergic Stimulation Phenomenon: Administering a pure non-selective or beta-1 selective beta-blocker (such as propranolol, metoprolol, or atenolol) to a patient with acute stimulant toxicity is strictly contraindicated.

• Pathophysiologic Mechanism: Beta-2 adrenergic receptors in peripheral arterial beds mediate vasodilation. When a beta-blocker selectively antagonizes beta-1 and beta-2 receptors in the presence of massive circulating catecholamines, the counter-regulatory vasodilatory mechanism is abolished. Unchecked catecholamines act exclusively on vascular alpha-1 adrenergic receptors, precipitating catastrophic unopposed alpha vasoconstriction.
• Clinical Consequences: Paradoxical, malignant surges in systemic blood pressure, acute aortic dissection, severe coronary arterial spasm, acute left ventricular failure, and extensive transmural myocardial infarction.

Hemodynamic Crisis Protocol

• First-Line Pharmacotherapy: Administer intravenous benzodiazepines (lorazepam 2 to 4 mg IV or diazepam 5 to 10 mg IV every 5 to 10 minutes). Benzodiazepines enhance central GABAergic tone, suppressing sympathetic outflow from the brainstem rostral ventrolateral medulla, reducing heart rate, blood pressure, psychomotor agitation, and myocardial oxygen demand.
• Coronary Vasospasm & Severe Hypertension:
  • Sublingual or IV Nitroglycerin: Direct nitric oxide donor inducing rapid coronary and systemic venodilation/arteriodilation.
  • Intravenous Calcium Channel Blockers: Diltiazem (0.25 mg/kg IV bolus followed by infusion) or verapamil provides coronary vasodilation and controls supraventricular tachycardias.
  • Phentolamine: A competitive, non-selective alpha-1 and alpha-2 adrenergic antagonist (1 to 5 mg IV bolus every 5 to 10 minutes) is the definitive antidote for severe stimulant-induced hypertensive crisis and refractory coronary spasm.
  • Combined Alpha-Beta Blockade: If beta-blockade is deemed clinically necessary after adequate vasodilatory and benzodiazepine therapy, labetalol (a combined alpha-1 and non-selective beta blocker with a 1:7 alpha-to-beta antagonistic ratio parenterally) may be utilized with caution, although pure vasodilators remain preferred.

STIMULANT-INDUCED HYPERTENSIVE CRISIS / CHEST PAIN ALGORITHM:

[Acute Cocaine / Methamphetamine Toxicity Presenting with Chest Pain / Malignant Hypertension]
                                  │
                                  ▼
       [Administer High-Dose IV Benzodiazepines (Lorazepam 2-4 mg IV)]
                     (Attenuates Central Sympathetic Surge)
                                  │
         ┌────────────────────────┴────────────────────────┐
         ▼                                                 ▼
[Persistent Coronary Ischemia / Chest Pain]      [Persistent Severe Hypertension (SBP > 180)]
         │                                                 │
         ▼                                                 ▼
[Sublingual/IV Nitroglycerin or Diltiazem]       [IV Phentolamine (1-5 mg IV) or Nitroglycerin]
         │                                                 │
         └────────────────────────┬────────────────────────┘
                                  ▼
            [STRICT CONTRAINDICATION: PURE BETA-BLOCKERS]
                 (Avoid Metoprolol, Propranolol, Atenolol)

Hyperthermia, Rhabdomyolysis & Acute Kidney Injury

Severe stimulant toxicity frequently manifests as malignant hyperthermia, where core body temperature exceeds $40.5^\circ\text{C}$ ($105^\circ\text{F}$). This hyperpyrexic state results from the convergence of:

• Uncontrolled, violent psychomotor agitation and muscle fasciculations producing massive metabolic heat.
• Intense cutaneous vasoconstriction (alpha-1 mediated) preventing convective and evaporative heat loss.
• Direct hypothalamic dopaminergic dysregulation disrupting central thermoregulatory set points.

Downstream Pathological Cascade:

1. Rhabdomyolysis: Hyperpyrexia and continuous muscle contraction trigger skeletal muscle cell membrane breakdown, releasing massive quantities of myoglobin, creatine kinase (CK $>10,000\text{–}100,000\text{ U/L}$), potassium, and phosphate into the circulation.
2. Myoglobinuric Acute Kidney Injury (AKI): Filtered myoglobin precipitates in renal tubules under acidic conditions, causing direct tubular cytotoxicity, renal vasoconstriction, and cast nephropathy.
3. Disseminated Intravascular Coagulation (DIC): Extreme temperatures trigger widespread endothelial injury, activating systemic coagulation cascades, consuming platelets and clotting factors, and precipitating catastrophic microvascular thrombosis and hemorrhagic shock.

Excited Delirium & Agitation Management

Excited delirium is an extreme psychiatric and physiological emergency characterized by acute delirium, intense psychomotor agitation, paranoia, hallucinations, diaphoresis, hyperthermia, and superhuman physical exertion followed by sudden cardiopulmonary collapse.

• Primary Treatment: Immediate parenteral sedation with intravenous or intramuscular benzodiazepines (midazolam 5 to 10 mg IM or lorazepam 2 to 4 mg IV/IM), repeated rapidly until the patient is calm. Immediate external active cooling (ice-water immersion, evaporative mist cooling, ice packs in axillary and inguinal creases) and aggressive intravenous crystalloid hydration ($20\text{ to }40\text{ mL/kg/hr}$ of normal saline adjusted to maintain urine output $\ge 100\text{–}200\text{ mL/hr}$).
• The Antipsychotic Hazard: First-generation antipsychotics (e.g., haloperidol, fluphenazine) are contraindicated in acute stimulant hyperthermic toxicity. Haloperidol possesses potent anticholinergic and dopaminergic antagonist properties that impair sweating, block peripheral vasodilation, and severely cripple heat dissipation. Furthermore, haloperidol lowers the seizure threshold and significantly prolongs the QTc interval, exacerbating the risk of fatal ventricular dysrhythmias.

---

3. Pharmacotherapy Landscape & Landmark Clinical Trials

An essential concept for the CARN-AP examination is that there are NO FDA-approved medications for the treatment of Cocaine Use Disorder or Methamphetamine Use Disorder. All pharmacological interventions represent off-label applications supported by varying levels of clinical trial evidence.

The Landmark ADAPT-2 Trial (Trivedi et al., 2021)

The ADAPT-2 trial (Accelerating the Development of Addictive Pharmacotherapy Treatments for Methamphetamine Use Disorder), published in the New England Journal of Medicine, represents the most significant breakthrough in pharmacotherapy for methamphetamine use disorder to date:

• Study Design: A multisite, double-blind, two-stage, placebo-controlled randomized trial evaluating 403 adult participants with moderate-to-severe methamphetamine use disorder.
• Intervention Regimen:
  • Oral Extended-Release Bupropion: Initiated at 150 mg/day and titrated to 450 mg daily orally.
  • Injectable Extended-Release Naltrexone: Administered as 380 mg intramuscularly once every 3 weeks (rather than the standard 4-week interval used for alcohol and opioid dependence, to maintain higher steady-state therapeutic plasma concentrations).
• Mechanistic Synergy: Bupropion is a dual norepinephrine and dopamine reuptake inhibitor (NDRI) and non-competitive nicotinic acetylcholine receptor antagonist; it blunts dysphoric stimulant withdrawal and craving by restoring basal monoaminergic tone. Naltrexone is a mu-opioid receptor antagonist that modulates endogenous endorphin and dynorphin reward circuits implicated in stimulant reinforcement.
• Trial Findings: The weighted response rate (verified methamphetamine-negative urine drug screens) across stages was 13.6% in the active treatment group versus 2.5% in the placebo group ($P < 0.001$). The calculated Number Needed to Treat (NNT) was 9. Adverse events included gastrointestinal distress, nausea, headache, and insomnia, with no significant differences in serious adverse events.

Other Investigated Pharmacotherapies

• Topiramate: A sulfamate-substituted monosaccharide that enhances GABA-A receptor facilitation, antagonizes AMPA and kainate excitatory glutamate receptors, and weakly inhibits carbonic anhydrase. Multiple clinical trials demonstrate that topiramate (titrated slowly to 200 to 300 mg/day in divided doses) significantly promotes continuous abstinence and reduces craving in both cocaine and methamphetamine use disorders. Primary adverse effects include paresthesias, psychomotor slowing, cognitive word-finding difficulty ("dopamax"), and weight loss.
• Mirtazapine: A noradrenergic and specific serotonergic antidepressant ($NaSSA$) that acts as an antagonist at central presynaptic alpha-2 auto- and hetero-receptors, while blocking post-synaptic $5\text{-HT}_2$ and $5\text{-HT}_3$ receptors and histamine $H_1$ receptors. Randomized trials (Colfax et al., Coffin et al.) demonstrated that mirtazapine (30 mg daily at bedtime) significantly reduced methamphetamine use, depressive symptoms, and high-risk sexual behaviors among men who have sex with men (MSM) and transgender women.
• Psychostimulant Agonist Replacement Therapy: Off-label evaluation of prescription stimulants (e.g., extended-release mixed amphetamine salts, methylphenidate, lisdexamfetamine) has shown modest benefit in severe treatment-refractory cases, functioning analogously to methadone for opioids. However, evidence remains mixed, and diversion risk requires strict clinical oversight.

Summary of Off-Label Pharmacotherapies

---

4. Psychosocial Interventions: The Cornerstone of Treatment

Because pharmacotherapies provide only adjunctive benefit, psychosocial and behavioral interventions constitute the primary standard of care for stimulant use disorders.

PSYCHOSOCIAL HIERARCHY OF EVIDENCE IN STIMULANT USE DISORDER:

  ┌────────────────────────────────────────────────────────┐
  │  CONTINGENCY MANAGEMENT (CM)                           │ ── Highest Effect Size (d ≈ 0.60 - 0.80)
  │  (Objective reinforcement, voucher / fishbowl system)  │    Superior retention and verified abstinence
  ├────────────────────────────────────────────────────────┤
  │  COGNITIVE BEHAVIORAL THERAPY (CBT)                    │ ── Moderate Effect Size (d ≈ 0.35 - 0.45)
  │  (Relapse prevention, trigger analysis, coping skills) │    Durable post-treatment relapse prevention
  ├────────────────────────────────────────────────────────┤
  │  THE MATRIX MODEL                                      │ ── Comprehensive 16-Week IOP Platform
  │  (Structured behavioral, psychoeducation, family, UDS) │    Optimized for ambulatory methamphetamine care
  └────────────────────────────────────────────────────────┘

Contingency Management (CM)

Contingency Management is grounded in principles of operant conditioning, delivering immediate, tangible positive reinforcement (rewards) upon objective verification of the target behavior (e.g., stimulant-negative urine drug screens):

• Empirical Stature: Over three decades of randomized controlled trials demonstrate that CM produces the largest effect size ($d \approx 0.60\text{ to }0.80$) of any therapeutic intervention for stimulant use disorders, significantly outperforming standard counseling, 12-step programs, and pharmacotherapy in achieving continuous abstinence and treatment retention.
• Implementation Models:
  • Voucher-Based Reinforcement (Higgins Model): Patients earn vouchers with monetary value redeemable for prosocial goods/services. The voucher value escalates with consecutive drug-negative urine tests (e.g., $2.50 for the first test, increasing by $1.25 for each successive negative test). A positive or missed test resets the voucher value back to baseline, introducing an immediate behavioral consequence.
  • Fishbowl Prize Method (Petry Model): Patients submitting negative urine screens earn draws from a prize bowl containing slips: 50% verbal affirmation ("Good job!"), 42% small prizes ($1 to $5), 7% medium prizes ($20), and 1% jumbo prizes ($100). The variable-ratio reinforcement schedule enhances engagement while significantly reducing programmatic costs.

Cognitive Behavioral Therapy (CBT)

CBT operates on the premise that substance-seeking behaviors are learned through classical conditioning, instrumental learning, and maladaptive cognitive schemas:

• Functional Analysis: Clinicians guide patients to analyze the "5 Ws" of stimulant use: Who they use with, What triggers use, Where they obtain/use, When urges peak, and Why they use (internal emotional states).
• Skill Acquisition: Focuses on craving management, developing refusal assertiveness, avoiding "people, places, and things," restructuring automatic euphoric recall, and managing the "Abstinence Violation Effect" (preventing a minor slip from escalating into a catastrophic relapse).

The Matrix Model

The Matrix Model is an intensive outpatient, 16-week programmatic platform developed specifically for stimulant (cocaine and methamphetamine) dependence:

• Multimodal Integration: Combines weekly individual counseling, early recovery skills groups, 12-step facilitation, relapse prevention groups, family education workshops, and mandatory, twice-weekly randomized urine toxicology monitoring.
• Therapeutic Stance: The clinician serves as an active, authentic, non-confrontational "coach," fostering self-efficacy and establishing predictable structure during the vulnerable early withdrawal period.